Organised by the FIP New Generation of Pharmaceutical Scientists SIG in collaboration with the FIP Early Career Pharmaceutical Group, the FIP Personalised and Precision Medicine SIG & the FIP Scientific Secretary
Chair(s)
Prof. Giovanni Pauletti, FIP Board of Pharmaceutical Sciences, USA & Dr Rebecka Isaksson, FIP Scientific Secretary, UK
Introduction:
Tailoring pharmacotherapy to the needs of individual cancer patients requires a deep understanding of cancer biology and the development of targeted therapies. This session will delve into the pharmaceutical science of developing new cancer treatments, highlighting recent drug discovery, formulation, and delivery advancements and new tools for disease modelling, to achieve more suitable and translational models. The session will explore the latest research on personalised medicine, immunotherapy, and/or targeted therapies, and the impact of cancer metabolism and tumour microenvironments on therapeutic response. Additionally, the session will provide an overview of recently approved oncology drugs and their impact on patient outcomes. The session aims to cater to high-level discourse with leaders in the field, while retaining some elements geared towards early career professionals. We aim to highlight the work of early career scientists working in the cancer research field in academia or industry.
Programme:
| 09:00 – 09:05 | Introduction by the chairs |
| 09:05 – 09:20 | From beside to bench and back: How patient-derived organoids and 3D models can improve cancer research and therapy decisions |
| Dr. Maria Virginia Giolito, Pole of Pharmacology and Therapeutics (FATH), Institute of Experimental and Clinical Research (IREC), UCLouvain, Belgium | |
| 09:20 – 09:45 | Leverage the power of AI for precision & personalised medicine |
| Dr. Stephanie Huang, University of Minnesota, USA | |
| 09:45 – 10:10 | Implementation of PGx and policies affecting change in the US |
| Prof. Pamala Jacobson, University of Minnesota, USA | |
| 10:10 – 10:30 | Panel discussion and wrap-up |
Learning objectives:
1. To stay informed on the latest advances in cancer drug discovery, pre-clinical personalised medicine research, and recent drug developments for potential clinical applications in cancer treatment.
2. To recognise the essential contributions of pharmaceutical scientists and early researchers in enhancing cancer therapies, studying cancer biology, and improving drug translation into clinics.
3. To explore the role of the tumour microenvironment, including cancer metabolism in the (non)response to cancer therapies, and the need to include it in research.
Take home messages:
Pharmaceutical scientists and basic and translational research in cancer are vital for understanding cancer biology, aiding the design of more selective and efficient drugs, improving the efficacy of existing drugs, and preventing resistance or relapse.
FIP Development Goals:
To learn more about these FIP Development Goals, click on the links below.
FIP Development Goal 2: Early Career Training Strategy
FIP Development Goal 4: Advanced and Specialist Development
FIP Development Goal 9: Continuing Professional Development Strategies
